Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

Serotonergic hallucinogens produce prominent changes in perception, mood and cognition that are largely mediated by activation of 5-HT2A receptors. Phenylalkylamine hallucinogens form one structural class in which 2,5-dimethoxy-substituted phenethylamines (the 2C-X family) and their α-methyl phenylisopropylamine congeners display high 5-HT2 receptor selectivity. Since about 2010 a new subclass of designer phenethylamine hallucinogens — N-benzylphenethylamines or "NBOMes" — has appeared on the recreational market. Addition of an N-benzyl substituent markedly increases 5-HT2A binding affinity and, reportedly, human potency; substances such as 25I-NBOMe and 25B-NBOMe have been sold on blotter paper and in other forms and associated with numerous toxicity cases and fatalities. Halberstadt sets out to review the structure–activity relationships, behavioural pharmacology, metabolism and clinical toxicology of NBOMe compounds. The chapter summarises in vitro binding and mutagenesis work, rodent behavioural assays used to probe hallucinogenic activity and a series of reported clinical and forensic cases (51 individual toxicity cases discussed in the extracted text), with emphasis on complications such as seizures, hyperthermia and rhabdomyolysis that characterise severe NBOMe intoxication.

The extracted text does not present a formal Methods section describing search strategy, inclusion criteria or systematic review methods. Instead, the chapter comprises a narrative synthesis of multiple lines of evidence: in vitro receptor-binding and mutagenesis studies, homology modelling, rodent behavioural pharmacology (notably the head-twitch response, HTR, and locomotor assays), metabolism experiments (microsomal clearance and metabolite identification), and clinical/forensic case reports and poison-centre data. For the preclinical evidence, Halberstadt and colleagues report binding affinities (Ki) at recombinant or native 5-HT2A and 5-HT2C sites, mutational analyses of receptor residues implicated in ligand interactions, and functional/efficacy measures from cell assays and behavioural readouts such as the HTR in mice. Behavioural assays used include magnetometer-based detection of the HTR in C57BL/6J mice and locomotor activity testing after different routes of administration. Clinical information is drawn from published case reports, case series and surveillance databases. The chapter collates individual clinical presentations (narrative vignettes) and summary comparisons, including a comparison cited between 148 NBOMe exposures and 193 2C-X exposures reported to the US National Poison Data System. Where available, toxicological confirmation by LC-MS, LC-MS/MS or GC-MS and measured drug concentrations in blood/urine/brain are reported in the case descriptions. The extracted text does not specify any quantitative synthesis methods, risk-of-bias assessment or formal inclusion/exclusion rules for case selection.

Structure–activity relationships: Addition of an N-benzyl group to 2,5-dimethoxy phenethylamines substantially increases 5-HT2A receptor affinity in many compounds. Homology models and mutagenesis point to aromatic stacking between the N-benzyl ring and Phe339 in transmembrane domain 6 as a key stabilising interaction; mutation of Phe339 selectively impairs affinity and agonist activity of NBOMes. An oxygenated substituent at the ortho position of the N-benzyl ring (the NBOMe motif) further increases 5-HT2A affinity, plausibly by acting as a hydrogen-bond acceptor; however, mutagenesis data regarding interaction with Tyr370 are inconsistent in the extracted text. Steric and positional constraints on the N-benzyl substituent are evident: ortho-methoxy substitution yields higher affinity and potency than meta- or para-methoxy isomers, and bulky para substitutions markedly reduce affinity. Functional potency and selectivity: In mice, 25I-NBOMe induces the HTR with an ED50 of 78 μg/kg (0.17 μmol/kg) after subcutaneous administration, slightly less potent than LSD (ED50 53 μg/kg, 0.13 μmol/kg) and roughly tenfold more potent than 2C-I (ED50 830 μg/kg). Other NBOMes show variable potencies (25I-NBMD ED50 1.13 mg/kg). Efforts to engineer 5-HT2A-selective NBOMes identified analogues such as 25CN-NBOH and rigidified derivatives (e.g. trans-DMBMPP and its (S,S) enantiomer) that display moderate-to-high selectivity for 5-HT2A versus 5-HT2C sites and produce the HTR at submilligram-to-milligram doses (25CN-NBOH ED50 0.36 mg/kg). Pharmacokinetics and metabolism: In vitro microsomal clearance is much higher for NBOMes than for parent 2C-X phenethylamines; for example, 2C-I intrinsic clearance is reported as 0.20 L/kg/h whereas 25I-NBOMe clearance is 4.1 L/kg/h. Because NBOMe clearance exceeds estimated hepatic blood flow (reported as ~1.2 L/h/kg), extensive first-pass metabolism likely explains why NBOMes are generally inactive by oral administration and are instead used sublingually or buccally. Major metabolic routes include O-desmethylation and N-dealkylation; O-desmethyl metabolites are rapidly conjugated with glucuronic acid, which limits systemic exposure, though NBOMe glucuronide conjugates might retain affinity in some cases. Behavioural assays: Locomotor assays in mice show a dose-dependent profile similar to phenylalkylamine hallucinogens, with low-to-moderate doses increasing activity and higher doses reducing it; 25I-NBOMe produced effects consistent with peripheral first-pass metabolism differences between routes (SC active, IP less active). Clinical and toxicological case data: The chapter summarises 51 individual cases of NBOMe toxicity extracted from the literature and cites surveillance figures: 148 NBOMe toxicity reports to the US National Poison Data System between September 2012 and September 2014, and 19 fatalities linked to 25I-NBOMe reported by the US DEA between March 2012 and August 2013. Clinical features across cases cluster into two broad severity categories. Less severe presentations (24 of the 51 described cases) commonly include hallucinations, agitation, confusion, diaphoresis, hypertension and tachycardia; many of these resolved with minimal intervention (restraint, benzodiazepines or supportive care). Severe presentations (23 of the 51 cases) involved seizures, hyperthermia, metabolic acidosis, rhabdomyolysis, renal impairment and multi-organ failure; many required ICU care, intubation, hemodialysis and prolonged hospitalisation, and some were fatal. Of the 23 moderate-to-severe cases, 14 had at least one of rhabdomyolysis, metabolic acidosis or renal failure. Seizures were common in that subgroup: 12/14 (85.7%) of cases with rhabdomyolysis, metabolic acidosis or renal failure had seizures. Hyperthermia was recorded in more than half of the severe cases (12/23). Features consistent with serotonin syndrome (notably clonus) were relatively uncommon across all reported cases (9/51), and in at least one instance clonus co-occurred with SSRI co-administration. Drug concentrations reported in case vignettes vary widely. Plasma or blood concentrations in non-fatal cases were often in the sub-microgram-per-litre range (examples include 0.089 μg/L and 0.76 μg/L), whereas several fatal postmortem concentrations reached much higher values (examples given include 19.8 μg/L and 28 μg/L in postmortem specimens). In a small sample of ten recreational cases, plasma 25B-NBOMe concentrations ranged from 0.7 to 10.7 μg/L. The extracted text also notes instances in which oral administration produced relatively higher levels of parent 2C-X compounds due to first-pass N-dealkylation (one clinical report showed 2C-I >> 25I-NBOMe in serum after inadvertent oral ingestion). Comparative surveillance analysis: A comparison of 148 NBOMe exposures versus 193 2C-X exposures in the poison-centre database indicated broadly similar clinical features, but single-episode seizures were significantly more likely with NBOMes (8.8% vs 3.1%).

Halberstadt interprets the collected evidence as showing that N-benzyl substitution markedly enhances 5-HT2A receptor affinity and behavioural potency of 2,5-dimethoxy phenethylamines, with aromatic stacking at Phe339 and positional hydrogen-bonding interactions of an ortho-oxygenated N-benzyl ring helping to explain the effect. Behavioural pharmacology in rodents (HTR and locomotor assays) aligns with binding data: NBOMes such as 25I-NBOMe are highly potent in the HTR, with potency approaching that of LSD in mice. On clinical toxicology, the authors emphasise that NBOMe use has been associated with a spectrum of adverse effects. Many exposures are self-limiting and respond to supportive care, but a substantial minority progress to life-threatening complications including seizures, rhabdomyolysis, metabolic acidosis, renal failure and death. The available case literature and poison-centre data suggest NBOMes provoke seizures more often than related 2C-X phenethylamines, and seizure-driven muscle damage together with hyperthermia and peripheral vasoconstriction likely contributes to the high incidence of rhabdomyolysis in severe cases. Unresolved questions and caveats noted in the chapter include incomplete understanding of the precise molecular interactions (for example, conflicting mutagenesis data regarding Tyr370), the potential contribution of metabolites or glucuronide conjugates to in vivo effects, and mechanisms underlying the apparently higher seizure propensity of NBOMes. The extracted text also highlights pharmacokinetic uncertainties: rapid microsomal clearance and extensive first-pass metabolism explain the typical non-oral route of abuse, but may lead to variable metabolite profiles that complicate interpretation of case toxicology. Implications discussed by the authors include the utility of NBOMe scaffolds for developing 5-HT2A-selective radioligands and PET tracers, and the clinical imperative for prompt supportive care when severe NBOMe toxicity presents. The chapter stresses that rapid recognition and management of seizures, hyperthermia and rhabdomyolysis is critical to prevent multi-organ failure. Limitations inherent in the evidence base are acknowledged implicitly: much of the clinical picture derives from case reports, variable confirmatory toxicology and surveillance data rather than prospective systematic clinical studies, and mechanistic conclusions draw on a mixture of in vitro, in silico and rodent data that do not fully resolve causality in humans.